#65 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
A recent expert review highlights concerning adverse effects associated with cannabis vaping that warrant clinical attention, particularly given the growing popularity of this consumption method among patients. While extensive research exists on smoked cannabis, evidence on vaping-specific harms remains limited, though preliminary studies of infrequent users suggest vaping may produce distinct physiological effects compared to smoking. The mechanisms underlying these vaping-related side effects are not fully characterized, but may involve exposure to heating byproducts, propylene glycol, and other inhaled substances that differ from combustion products in smoked cannabis. These findings are clinically relevant because patients increasingly prefer vaping as a presumed “safer” alternative to smoking, potentially without understanding its unique toxicological profile. Clinicians should counsel patients that vaping cannabis carries its own risk profile distinct from smoking and should inquire about vaping frequency and duration during cannabis use assessments. When counseling patients on cannabis consumption methods, clinicians should acknowledge that vaping is not necessarily a harm-free option and encourage further risk discussion until more robust safety data emerges.
“When patients vape cannabis, we’re seeing respiratory inflammation and airway hyperreactivity that mirrors what we observe with nicotine vaping, yet many assume it’s safer than smoking because there’s no combustion. The evidence tells us we need to counsel patients on this risk just as seriously as we do with any inhaled substance, because the absence of smoke doesn’t mean the absence of harm.”
💨 While cannabis vaping is often perceived as a safer alternative to smoking due to reduced combustion byproducts, emerging evidence suggests this assumption warrants reconsideration in clinical encounters. Infrequent users who vape cannabis may experience distinct pulmonary and systemic effects that differ from traditional smoking patterns, yet long-term safety data remain limited and are confounded by variability in device types, temperature settings, and product composition. The lack of standardized dosing and quality control in many cannabis products further complicates our ability to counsel patients accurately about vaping risks compared to other consumption routes. Clinicians should approach cannabis vaping with appropriate skepticism rather than accepting patient or industry claims of relative safety, and should document consumption method when taking substance use histories, as this information may become relevant to symptom attribution and treatment planning as our evidence base evolves.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: